In a perfect world, every emerging biopharma company would have a clear short- and long-term vision leading up to launch.

A Harvard Business School Healthcare Alumni Association Q&A with Elaina Shekhter, EPAM’s Chief Marketing & Strategy Officer.

Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...

Artiva Biotherapeutics’ CEO Fred Aslan, MD, identifies data points the company is prioritizing to demonstrate that results from certain trials will translate to similar efficacy across a range of ...

CordenPharma, a CDMO focused on peptides and peptide-based therapeutics, announced a partnership with Viking Therapeutics. The two companies will work together to ensure the production of Viking’s GLP ...

Auguston kicked off an animated session titled “The People Factor” by outlining all the ways in which the CEO role in ...

Traditional approaches to benchmarking brand performance have struggled to keep pace with industry dynamics. While individual ...

Partnership includes the development of combination products, including a fixed-dose combination of petrelintide and Roche’s dual GLP-1/GIP receptor agonist, CT-388, for weight management.

EVERSANA’s chief digital officer discusses recent developments in the pharma industry that are impacting its relationship ...

Dr. Hernan Bazan, CEO of South Rampart Pharma, discusses his company’s current pipeline.

Lunit announced the results of a prospective study that looked into the usage of AI in mammography screening. 1 According to ...

The FDA’s latest draft guidance on accelerated approval for new drugs, “Expedited Program for Serious Conditions—Accelerated ...